- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07950527
Topical Insulin Therapy for Persistent Corneal Epithelial Defects
The goal of this clinical trial is to learn if insulin eye drops, added to standard care, can treat persistent corneal epithelial defects (PEDs) in adults age 18 and older. A PED is a corneal surface wound, at least 2 mm across, that has not healed after more than 14 days of standard treatment such as lubricants, antibiotic drops, or a bandage contact lens. The main question it aims to answer is:
- Does adding insulin eye drops (1 IU/mL, four times daily) to standard care increase the proportion of eyes with complete corneal epithelial healing at 8 weeks?
The standard care plus insulin eye drops will be compared to standard care plus placebo eye drops (preservative-free saline) to see if insulin leads to more complete healing, faster healing, fewer recurrences, and better symptom relief. They will also assess the safety of the drops and their effects on corneal nerves.
Participants will:
- Be randomly assigned (1:1) to insulin or placebo drops. Neither participants nor the investigators assessing healing will know which drops are used. The study is single-center (Massachusetts Eye and Ear) and plans to enroll 40 participants, one eye each.
- Use the study drops four times daily for up to 8 weeks, along with standard care chosen by their cornea specialist, and return weekly for a fresh, refrigerated supply.
- Attend study visits at baseline and at weeks 1, 4, 8, and 12 for visual acuity testing, slit-lamp examination, fluorescein staining and photography of the defect, and imaging of corneal nerves (in vivo confocal microscopy).
- Complete symptom questionnaires (pain, foreign body sensation, light sensitivity) at baseline and week 8, and have corneal sensation tested before and after treatment.
- Have blood glucose monitored if they have diabetes.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
Corneal diseases are a leading cause of blindness worldwide according to the World Health Organization; many are in need of a corneal transplant but with a dearth of available tissue and proper medical/surgical expertise and care, the vast majority remain blind. A common cause of corneal blindness is untreated corneal epithelial defects. And as we explain below, the treatment options are very limited.
A persistent corneal epithelial defect (PED) is defined as a failure of the cornea to re-epithelialize within 2 weeks with standard treatment, and is caused by many underlying reasons, including nerve damage (e.g. in diabetes or herpetic infection), trauma, limbal stem cell deficiency, and severe inflammation of the ocular surface, among others. As PEDs are often refractory to conventional therapy (such as lubrication, bandage contact lenses, punctal occlusion, or surgical lid closure), they can progress to serious sequalae such as stromal ulceration, scarring, and even perforation. In particular, corneal scarring is a leading cause of blindness and visual disability, especially in regions with limited access to corneal transplantation. These risks underscore the need for improved and affordable treatments effective in promoting corneal epithelial healing, thereby limiting irreversible scarring and corneal opacity.
Rationale for Topical Insulin Therapy: Insulin is widely known as a metabolic hormone, but it also has growth-factor-like actions in various tissues, including the cornea. Importantly, insulin is widely available worldwide and can easily be compounded into eyedrops for use. The following preliminary evidence supports the use of topical insulin eye drops to promote corneal epithelial defect healing:
- Cell Growth (Trophic) Effects: Insulin can stimulate proliferation and migration of epithelial cells, essential for wound closure. At the ocular surface, exogenous insulin has been shown to stimulate corneal epithelial cell proliferation and migration, as well as the production of other growth factors involved in tissue regeneration. In preclinical studies, topical insulin significantly accelerated corneal epithelial wound healing. A recent study in diabetic mice demonstrated that insulin eye drops markedly promoted corneal re-epithelization and concurrently reduced corneal inflammatory responses vs. untreated controls.
- Ease of Preparation and Cost: Insulin eye drops are simple to prepare and inexpensive. Pharmacy compounding of topical insulin involves diluting readily available injectable human insulin into sterile saline or artificial tear solution to the desired concentration (1 IU/mL for topical administration).13,14
- No special storage or complex delivery devices are needed beyond standard dropper bottles. The simplicity of this formulation allows the wide availability of the therapy (even in resource-limited settings) at a fraction of the cost of biologics like Cenegermin.
- Preliminary Clinical Evidence: A growing number of case reports and small series have documented successful corneal healing with topical insulin. A small pilot study in 2024 treated patients with refractory PEDs using insulin eye drops as an adjunct to conventional therapy. The results were encouraging: 16 out of 23 patients (≈70%) showed complete healing or marked improvement in their epithelial defect, typically within 4-8 weeks of starting insulin therapy. Importantly, there were no significant adverse effects reported with topical insulin in this study. Wang et al. reported a series of 6 severe neurotrophic corneal ulcer patients (mix of diabetic and non-diabetic) in which all six achieved complete re-epithelialization on insulin drops within 1-4 weeks.
- Anti-Inflammatory Effects: Beyond simply "filling the gap" for NGF-nonresponsive patients, insulin might confer additional therapeutic benefits. Emerging evidence indicates that insulin has anti-inflammatory properties in the cornea. By binding insulin receptors on corneal and immune cells, it can modulate cytokine release and reduce the level of inflammatory biomarkers during wound healing.
- Insulin may promote corneal nerve regeneration, as increased corneal nerve fiber density and higher levels of neuropeptides (substance P and CGRP) in insulin-treated corneas, suggesting a restorative effect on the corneal innervation.
Knowledge Gaps and Unmet Need: Despite the scientific rationale and early reports cited above, critical gaps remain in our knowledge that must be addressed before insulin eye drops can be adopted as a standard treatment for corneal healing:
-
Lack of Rigorous Clinical Trials: To date, no sizeable randomized controlled trial (RCT) has been completed to definitively establish the efficacy of topical insulin for PEDs. The evidence for insulin's benefit comes from case series, small uncontrolled studies, or trials in very specific scenarios. A well-powered RCT is needed to provide high-quality evidence of efficacy and safety in a broader PED population.
-
Optimal Dosing and Treatment Regimen: There is no consensus on the effective dose, frequency, or duration of topical insulin for PEDs. Different studies have reported concentrations ranging from 0.5 U/mL up to 10 U/mL, with dosing frequencies between 4 and 6 times a day, and treatment courses from a few days to several weeks.17,21 Thus, standardizing the regimen is critical for reproducibility and regulatory approval.
-
Mechanistic Insights: While insulin's general effects on limbal stem cells are known, the precise mechanisms by which topical insulin promotes corneal epithelial defect closure are still being elucidated. A deeper understanding of the mechanism could help in optimizing combination therapies.
2. Specific Aims and Objectives
The primary objective is to determine whether adjunctive topical insulin (1 IU/mL, four times a day) increases the proportion of PED patients achieving complete corneal healing within 8 weeks, compared to placebo (saline) controls, under double masked conditions.
The secondary objective is to (1) compare time to defect healing vs. without insulin therapy; (2) to assess the durability of healing (rate of recurrence of defects after initial healing); (3) assess patient symptom improvements (pain) with insulin; (4) document safety issues or side effects of topical insulin on the eye; (5) to explore changes in corneal nerve density and sensitivity in insulin-treated eyes.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Varhainen vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Michael Cheung, MSCR, BSPS, CCRP
- Puhelinnumero: 617-573-6981
- Sähköposti: MCHEUNG0@MEEI.HARVARD.EDU
Tutki yhteystietojen varmuuskopiointi
- Nimi: Rohan B Singh, MD
- Puhelinnumero: 234-980-0015
Opiskelupaikat
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02114
- Massachusetts Eye and Ear
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Adults age 18 and older.
- 2. Focal corneal epithelial defect (≥ 2mm in longest dimension) present for > 14 days despite standard treatment (e.g. lubrication, antibiotic, bandage contact lens, etc.)
Exclusion Criteria:
- Active uncontrolled infection in the study eye.
- Impending corneal perforation (that requires urgent surgery).
- Other ocular comorbidities that would confound healing.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: Control
All control patients will continue to receive standard-of-care (SoC) therapy for PED as determined by the treating cornea specialist. SoC typically may include a preservative-free lubricant regimen, a fluoroquinolone antibiotic drop QID for prophylaxis, and use of a bandage contact lens or eyelid taping if appropriate. |
All patients will continue to receive standard-of-care (SoC) therapy for PED as determined by the treating cornea specialist. SoC typically may include a preservative-free lubricant regimen, a fluoroquinolone antibiotic drop QID for prophylaxis, and use of a bandage contact lens or eyelid taping if appropriate. |
|
Active Comparator: Treatment
In the insulin arm, patients will receive topical regular human insulin diluted to 1 IU/mL in sterile preservative-free normal saline, applied as an eye drop four times a day (QID). |
The patients will receive topical regular human insulin diluted to 1 IU/mL in sterile preservative-free normal saline, applied as an eye drop four times a day (QID). Additionally, all interventional arm patients will continue to receive standard-of-care (SoC) therapy for PED as determined by the treating cornea specialist. SoC typically may include a preservative-free lubricant regimen, a fluoroquinolone antibiotic drop QID for prophylaxis, and use of a bandage contact lens or eyelid taping if appropriate. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Complete PED closure rate at 8 Weeks
Aikaikkuna: 8 weeks
|
The primary endpoint is the proportion of eyes in each group that achieve complete corneal epithelial defect closure by 8 weeks of treatment. "Complete healing" is defined as 100% re-epithelialization of the cornea with no fluorescein staining defect remaining, confirmed on two consecutive visits including the final 8-week visit. We will document epithelial closure using fluorescein staining and slit-lamp photography at each follow-up. An independent masked ophthalmologist will review images to confirm healing status, using standardized criteria. |
8 weeks
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Time to Healing
Aikaikkuna: 8 weeks
|
For each eye that heals during the study, we will record the number of days from treatment initiation to the first visit at which the defect is fully closed. We hypothesize the insulin group will have a faster time-to-healing (accelerated re-epithelialization) compared to controls. We will use survival analysis methods (Kaplan-Meier curves and log-rank test) to compare time-to-healing distributions. |
8 weeks
|
|
Partial Healing (Defect Reduction)
Aikaikkuna: 8 weeks
|
In eyes that do not completely heal, we will assess the change in defect size. Specifically, the percentage reduction in defect area from baseline to 8 weeks (measured from corneal staining photographs) will be calculated. We will compare the mean reduction and the proportion of eyes achieving at least a 50% reduction in area between groups. This will capture any clinically meaningful improvement short of full closure. |
8 weeks
|
|
Recurrence Rate
Aikaikkuna: From documented complete epithelial healing through 12 weeks after completion of the 8-week treatment period.
|
Recurrence is defined as the development of a new corneal epithelial defect greater than 1 mm in diameter at the same anatomical location following documented complete epithelial healing. The outcome will be reported as the percentage of participants who experience at least one recurrence during the 12-week follow-up period after completion of the 8-week treatment phase, among participants whose epithelial defects healed during treatment. |
From documented complete epithelial healing through 12 weeks after completion of the 8-week treatment period.
|
|
Symptom Relief
Aikaikkuna: 8 weeks
|
Ocular surface symptoms and their impact on vision-related functioning will be measured using the validated 12-item Ocular Surface Disease Index (OSDI) questionnaire at baseline and Week 8. The OSDI total score ranges from 0 to 100, with higher scores indicating greater symptom severity and functional impairment. The outcome will be reported as the change in total OSDI score from baseline to Week 8, calculated as the Week 8 score minus the baseline score. Negative values indicate improvement in symptoms. |
8 weeks
|
|
Safety Outcomes
Aikaikkuna: 8 weeks
|
The number of participants experiencing at least one adverse event during the 8-week treatment period will be recorded and reported for each treatment group. Adverse events will include ocular and systemic events, including ocular surface inflammation, corneal edema, corneal haze, ocular infection, and systemic adverse events potentially associated with treatment. Each participant experiencing one or more adverse events will be counted once for this outcome. |
8 weeks
|
|
Corneal Sub-Basal Nerve Fiber Density
Aikaikkuna: 8 weeks
|
Corneal sub-basal nerve fiber length density will be quantified using in vivo confocal microscopy (IVCM) at baseline and at all scheduled post-treatment follow-up visits. Nerve fiber length density will be expressed as the total length of visible sub-basal corneal nerve fibers per unit area of corneal tissue (mm/mm²). The outcome will be reported as the change in nerve fiber length density from baseline at each follow-up visit, calculated as the value at the respective follow-up visit minus the baseline value. Positive values indicate an increase in corneal nerve fiber length density. |
8 weeks
|
|
Corneal Sensitivity
Aikaikkuna: 8 weeks
|
Corneal sensitivity will be measured using a Cochet-Bonnet esthesiometer at baseline and at all scheduled post-treatment follow-up visits. Corneal sensitivity will be quantified as the maximum nylon filament length, expressed in centimeters (cm), that elicits a reproducible corneal sensation or blink response. The outcome will be reported as the change in filament length from baseline at each follow-up visit, calculated as the value at the respective follow-up visit minus the baseline value. Positive values indicate improved corneal sensitivity. |
8 weeks
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojen puheenjohtaja: Reza Dana, MD, MSc, MPH, Massachusetts Eye and Ear, Harvard Medical School
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, Foster CS, Affeldt J, Seedor JA, Afshari NA, Chao W, Allegretti M, Mantelli F, Dana R. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial. Ophthalmology. 2020 Jan;127(1):14-26. doi: 10.1016/j.ophtha.2019.08.020. Epub 2019 Aug 26.
- Wang AL, Weinlander E, Metcalf BM, Barney NP, Gamm DM, Nehls SM, Struck MC. Use of Topical Insulin to Treat Refractory Neurotrophic Corneal Ulcers. Cornea. 2017 Nov;36(11):1426-1428. doi: 10.1097/ICO.0000000000001297.
- Fai S, Ahem A, Mustapha M, Mohd Noh UK, Bastion MC. Randomized Controlled Trial of Topical Insulin for Healing Corneal Epithelial Defects Induced During Vitreoretinal Surgery in Diabetics. Asia Pac J Ophthalmol (Phila). 2017 Sep-Oct;6(5):418-424. doi: 10.22608/APO.201780. Epub 2017 Aug 22.
- Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000 May;118(5):615-21. doi: 10.1001/archopht.118.5.615.
- Amparo F, Schaumberg DA, Dana R. Comparison of Two Questionnaires for Dry Eye Symptom Assessment: The Ocular Surface Disease Index and the Symptom Assessment in Dry Eye. Ophthalmology. 2015 Jul;122(7):1498-503. doi: 10.1016/j.ophtha.2015.02.037. Epub 2015 Apr 8.
- Stuard WL, Titone R, Robertson DM. The IGF/Insulin-IGFBP Axis in Corneal Development, Wound Healing, and Disease. Front Endocrinol (Lausanne). 2020 Mar 3;11:24. doi: 10.3389/fendo.2020.00024. eCollection 2020.
- Yang S, Zhang Y, Zhang Z, Dan J, Zhou Q, Wang X, Li W, Zhou L, Yang L, Xie L. Insulin Promotes Corneal Nerve Repair and Wound Healing in Type 1 Diabetic Mice by Enhancing Wnt/beta-Catenin Signaling. Am J Pathol. 2020 Nov;190(11):2237-2250. doi: 10.1016/j.ajpath.2020.08.006. Epub 2020 Aug 26.
- Song F, Xue Y, Dong D, Liu J, Fu T, Xiao C, Wang H, Lin C, Liu P, Zhong J, Yang Y, Wang Z, Pan H, Chen J, Li Y, Cai D, Li Z. Insulin Restores an Altered Corneal Epithelium Circadian Rhythm in Mice with Streptozotocin-induced Type 1 Diabetes. Sci Rep. 2016 Sep 9;6:32871. doi: 10.1038/srep32871.
- Soares RJDSM, Arede C, Sousa Neves F, da Silva Fernandes J, Cunha Ferreira C, Sequeira J. Topical Insulin-Utility and Results in Refractory Neurotrophic Keratopathy in Stages 2 and 3. Cornea. 2022 Aug 1;41(8):990-994. doi: 10.1097/ICO.0000000000002858. Epub 2021 Sep 3.
- Jain P, Hariani A, Gupta I, Reddy G. Management of refractory persistent epithelial defect treatment with topical insulin: An Indian pilot study. Indian J Ophthalmol. 2025 Oct 1;73(10):1513-1519. doi: 10.4103/IJO.IJO_2935_24. Epub 2025 Sep 25.
- Bievel Radulescu R, Ferrari S, Stanca HT, Ponzin D. Topical insulin as a novel treatment for persistent epithelial defects and other ocular surface disorders: a systematic review. Graefes Arch Clin Exp Ophthalmol. 2025 Sep;263(9):2427-2445. doi: 10.1007/s00417-025-06840-7. Epub 2025 May 17.
- Krolo I, Behaegel J, Termote K, de Bruyn B, De Schepper M, Oellerich S, Ni Dhubhghaill S. The role of topical insulin in ocular surface restoration: A review. Surv Ophthalmol. 2024 Sep-Oct;69(5):805-817. doi: 10.1016/j.survophthal.2024.04.003. Epub 2024 Apr 10.
- Vicario-de-la-Torre M, Puebla-Garcia V, Ybanez-Garcia L, Lopez-Cano JJ, Gonzalez-Cela-Casamayor MA, Brugnera M, Burgos-Blasco B, Diaz-Valle D, Gegundez-Fernandez JA, Benitez-Del-Castillo JM, Herrero-Vanrell R. Topical Insulin Eye Drops: Stability and Safety of Two Compounded Formulations for Treating Persistent Corneal Epithelial Defects. Pharmaceutics. 2024 Apr 24;16(5):580. doi: 10.3390/pharmaceutics16050580.
- Chen S, Li Y, Song W, Cheng Y, Gao Y, Xie L, Huang M, Yan X. Insulin eye drops improve corneal wound healing in STZ-induced diabetic mice by regulating corneal inflammation and neuropeptide release. BMC Ophthalmol. 2024 Apr 9;24(1):155. doi: 10.1186/s12886-024-03436-3.
- Peterson C, Chandler HL. Insulin facilitates corneal wound healing in the diabetic environment through the RTK-PI3K/Akt/mTOR axis in vitro. Mol Cell Endocrinol. 2022 May 15;548:111611. doi: 10.1016/j.mce.2022.111611. Epub 2022 Feb 26.
- Titone R, Zhu M, Robertson DM. Insulin mediates de novo nuclear accumulation of the IGF-1/insulin Hybrid Receptor in corneal epithelial cells. Sci Rep. 2018 Mar 12;8(1):4378. doi: 10.1038/s41598-018-21031-7.
- Dai X, Jensen A, Dun C, Karakus S, Rajaii F, Woreta F. Cost and Prescriber and Patient Characteristics of Cenegermin Use in the Medicare Population. Am J Ophthalmol. 2023 Jun;250:12-19. doi: 10.1016/j.ajo.2023.01.025. Epub 2023 Feb 6.
- Choudhry HS, Pei M, Mothy D, Scarfuto J, Mian SI. Real-World Safety Profile of Cenegermin Per FDA Adverse Event Reporting System. J Ocul Pharmacol Ther. 2025 Aug;41(6):339-346. doi: 10.1089/jop.2025.0023. Epub 2025 May 7.
- Li Y, Yang H, Gao Y, He W. Ocular adverse events of cenegermin used in neurotrophic keratopathy: an analysis of the FDA adverse event reporting system database. Expert Opin Drug Saf. 2024 Mar;23(3):385-391. doi: 10.1080/14740338.2023.2251389. Epub 2023 Aug 28.
- Dua HS, Said DG, Messmer EM, Rolando M, Benitez-Del-Castillo JM, Hossain PN, Shortt AJ, Geerling G, Nubile M, Figueiredo FC, Rauz S, Mastropasqua L, Rama P, Baudouin C. Neurotrophic keratopathy. Prog Retin Eye Res. 2018 Sep;66:107-131. doi: 10.1016/j.preteyeres.2018.04.003. Epub 2018 Apr 23.
- Singh RB, Dohlman TH, Ivanov A, Hall N, Ross C, Elze T, Miller JW, Lorch A, Yuksel E, Yin J, Dana R; IRIS Registry Data Analytic Center Consortium. Corneal Opacity in the United States: An American Academy of Ophthalmology IRIS(R) Registry (Intelligent Research in Sight) Study. Ophthalmology. 2025 Jan;132(1):52-61. doi: 10.1016/j.ophtha.2024.07.005. Epub 2024 Jul 8.
- Katzman LR, Jeng BH. Management strategies for persistent epithelial defects of the cornea. Saudi J Ophthalmol. 2014 Jul;28(3):168-72. doi: 10.1016/j.sjopt.2014.06.011. Epub 2014 Jul 2.
- Thia ZZ, Ho YT, Shih KC, Tong L. New developments in the management of persistent corneal epithelial defects. Surv Ophthalmol. 2023 Nov-Dec;68(6):1093-1114. doi: 10.1016/j.survophthal.2023.06.001. Epub 2023 Jun 8.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
- 2026P002049
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-jaon aikakehys
The IPD will be available from December 1 till the study is concluded.
IPD-jaon käyttöoikeuskriteerit
The IPD will be available on request from Mr. Michael Cheung, Clinical Research Project Manager.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- ICF
- CSR
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .